CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 17, 2007--Sirtris
Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company
focused on discovering and developing small molecule drugs to treat
diseases of aging, announced today that it presented data from
pre-clinical and Phase 1a studies at the 6th Annual Metabolic Diseases
Drug Discovery and Development World Summit in San Diego, California
on July 17, 2007. As previously announced, Jill Milne, Ph.D., Senior
Director of Biology at Sirtris, delivered a keynote address "SIRT1
Activation: A Novel Mechanism for Treating Type 2 Diabetes."
Dr. Milne presented data which showed that SRT501, Sirtris'
proprietary formulation of resveratrol, reduces glucose and improves
insulin sensitivity in multiple pre-clinical models of Type 2
Diabetes. Dr. Milne also presented pharmacokinetic (PK) data from a
Phase 1a study conducted by Sirtris in which healthy volunteers who
were dosed with SRT501 had an improved exposure as compared with other
published studies. Both the area under the curve concentrations (AUC)
as well as the maximal concentrations (Cmax) were shown to be improved
with SRT501 as compared with literature values for resveratrol. SRT501
is currently being tested in a Phase 1b study in patients with Type 2
Furthermore, Dr. Milne presented data with certain Sirtris
proprietary novel chemical SIRT1 activators, structurally unrelated to
resveratrol, which were shown to reduce glucose, improve insulin
sensitivity, improve glucose tolerance, and increase the number and
function of mitochondria in multiple pre-clinical models of Type 2
Diabetes. In addition, studies in a pre-clinical model demonstrate
improved insulin sensitivity in muscle, liver, and fat cells.
"Sirtris scientists continue to make significant progress in the
development of SIRT1 activators for diseases of aging such as Type 2
Diabetes. Indeed, the new data presented today further extend Sirtris'
scientific leadership in advancing sirtuin modulators as a new class
of innovative therapeutics," said Christoph Westphal, M.D., Ph.D.,
Chief Executive Officer of Sirtris.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the progress of
pre-clinical and clinical studies of SIRT1 activators, the results of
pre-clinical studies as compared with other published studies,
Sirtris' position in the sirtuin field, and the potential for sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company's product candidates has received regulatory approvals, the
potential inability of the Company to gain market acceptance of the
Company's product candidates, and those other risks factors that can
be found in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events
or circumstances that occur after the date of this release.
CONTACT: Investor Contact:
Sirtris Pharmaceuticals, Inc.
Michelle Dipp, M.D., Ph.D., 617-252-6920
Sheryl Seapy, 949-608-0841
SOURCE: Sirtris Pharmaceuticals, Inc.